Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial

[1]  Awad Ag.  Subjective Response to Neuroleptics in Schizophrenia , 1993 .

[2]  T. Barnes.  A Rating Scale for Drug-Induced Akathisia , 1989, British Journal of Psychiatry.

[3]  Charles M Beasley,et al.  Olanzapine versus Placebo and Haloperidol , 1996, Neuropsychopharmacology.

[4]  R. Rosenheck,et al.  A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. , 1997, The New England journal of medicine.

[5]  K. Wells,et al.  Quality of life of seriously mentally ill persons in Mississippi. , 1991, Hospital & community psychiatry.

[6]  N. Lurie,et al.  Does capitation affect the health of the chronically mentally ill? Results from a randomized trial. , 1992, JAMA.

[7]  John E. Ware,et al.  SF-36 physical and mental health summary scales : a user's manual , 1994 .

[8]  R. Heslegrave,et al.  Preliminary validation of a conceptual model to assess quality of life in schizophrenia , 1995, Schizophrenia Research.

[9]  R. Buchanan,et al.  Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. , 1994, The American journal of psychiatry.

[10]  M. Woerner,et al.  Anchoring the BPRS: an aid to improved reliability. , 1988, Psychopharmacology bulletin.

[11]  H. Meltzer,et al.  Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. , 1990, Hospital & community psychiatry.

[12]  A. Lehman.  The well-being of chronic mental patients. , 1983, Archives of general psychiatry.

[13]  R. Schaffarzick.  Health Care Technology and Quality of Care , 1987, Quality assurance and utilization review : official journal of the American College of Utilization Review Physicians.

[14]  Nancy H. Covell,et al.  Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. , 1996, Psychopharmacology bulletin.

[15]  S. Marder,et al.  Subjective response to antipsychotic drugs. , 1981, Archives of general psychiatry.

[16]  T. Kircher,et al.  Subjective effects of neuroleptics predict compliance , 1994 .

[17]  F. Sainfort,et al.  A new patient focused index for measuring quality of life in persons with severe and persistent mental illness , 1993, Quality of Life Research.

[18]  A. Stewart,et al.  Using health status measures with the seriously mentally ill in health services research. , 1996, Medical care.

[19]  W T Carpenter,et al.  The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. , 1984, Schizophrenia bulletin.

[20]  L. Dixon,et al.  Conventional antipsychotic medications for schizophrenia. , 1995, Schizophrenia bulletin.

[21]  W. Carpenter,et al.  Methodologic standards for treatment outcome research in schizophrenia. , 1981, The American journal of psychiatry.

[22]  A. Lehman,et al.  Convergent validation of quality of life assessments for persons with severe mental illnesses , 1993, Quality of Life Research.

[23]  Revicki Da.  Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia. , 1997 .

[24]  R. Heslegrave,et al.  Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life , 1995, European Psychiatry.

[25]  J. Ware.  SF-36 health survey: Manual and interpretation guide , 2003 .

[26]  D. Revicki,et al.  Preferences for schizophrenia‐related health states: a comparison of patients, caregivers and psychiatrists , 1996, International clinical psychopharmacology.

[27]  J. Kane,et al.  Drug therapy : schizophrenia , 1996 .

[28]  D. Sholomskas,et al.  Chronic schizophrenics in the community: are they able to report their social adjustment? , 1982, The American journal of orthopsychiatry.

[29]  A. Awad.  Subjective response to neuroleptics in schizophrenia. , 1993, Schizophrenia bulletin.

[30]  D. Revicki.  Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia. , 1997, Journal of psychiatry & neuroscience : JPN.

[31]  A. Lehman,et al.  The quality of life of chronic patients in a state hospital and in community residences. , 1986, Hospital & community psychiatry.

[32]  T. Hogan,et al.  Measurement of therapeutic response in schizophrenia A critical survey , 1991, Schizophrenia Research.

[33]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[34]  L. Linn,et al.  Chronic mental patients: the quality of life issue. , 1982, The American journal of psychiatry.

[35]  R. Tamura,et al.  Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. , 1997, The American journal of psychiatry.

[36]  J. Larson.  The MOS 36-Item Short form Health Survey , 1997, Evaluation & the health professions.

[37]  G. Tollefson,et al.  Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. , 1997, American Journal of Psychiatry.

[38]  S. Marder,et al.  Psychopharmacologic treatment of schizophrenia. , 1993, Schizophrenia bulletin.